Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
50
URGN Quote, Financials, Valuation and Earnings
Last price:
$21.27
Seasonality move
:
-3.17%
Day range:
$21.18 - $24.10
52-week range:
$3.42 - $30.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.47x
P/B ratio:
16.41x
Volume:
852.1K
Avg. volume:
770.4K
1-year change:
92.48%
Market cap:
$994.7M
Revenue:
$90.4M
EPS (TTM):
-$3.46
Analysts' Opinion
-
Consensus RatingUroGen Pharma Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.25, UroGen Pharma Ltd. has an estimated upside of 65.88% from its current price of $21.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $21.25.
Fair Value
-
According to the consensus of 7 analysts, UroGen Pharma Ltd. has 65.88% upside to fair value with a price target of $35.25 per share.
URGN vs. S&P 500
-
Over the past 5 trading days, UroGen Pharma Ltd. has underperformed the S&P 500 by -7.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
UroGen Pharma Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
UroGen Pharma Ltd. has grown year-over-year revenues for 18 quarters straight. In the most recent quarter UroGen Pharma Ltd. reported revenues of $27.5M.
Earnings Growth
-
UroGen Pharma Ltd. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter UroGen Pharma Ltd. reported earnings per share of -$0.69.
Enterprise value:
996.2M
EV / Invested capital:
--
Price / LTM sales:
10.47x
EV / EBIT:
--
EV / Revenue:
10.32x
PEG ratio (5yr expected):
-0.60x
EV / Free cash flow:
-6.91x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$84.9M
Return On Assets:
-66.98%
Net Income Margin (TTM):
-170.59%
Return On Equity:
--
Return On Invested Capital:
-209.52%
Operating Margin:
-99.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $77.3M | $89.4M | $96.5M | $25.2M | $27.5M | |
| Gross Profit | $67.9M | $80.7M | $84.9M | $22.8M | $24.2M | |
| Operating Income | -$71.2M | -$83.7M | -$133.4M | -$17.5M | -$27.4M | |
| EBITDA | -$69.5M | -$82.4M | -$131.4M | -$17.3M | -$26.7M | |
| Diluted EPS | -$4.23 | -$3.14 | -$3.46 | -$0.55 | -$0.69 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $125.1M | $121.6M | $182.1M | $295.1M | $168.5M | |
| Total Assets | $134.6M | $128.5M | $193.6M | $301.9M | $185M | |
| Current Liabilities | $19.8M | $19M | $25.8M | $32.8M | $42.2M | |
| Total Liabilities | $103.1M | $191.8M | $235.6M | $276.4M | $300.5M | |
| Total Equity | $31.5M | -$63.3M | -$42M | $25.5M | -$115.4M | |
| Total Debt | $616K | $73.7M | $99.5M | $121.9M | $129.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$81.9M | -$95.1M | -$143.7M | -$27.8M | -$47.5M | |
| Cash From Investing | $32.5M | -$91.9M | $95.7M | -$106.2M | $32.9M | |
| Cash From Financing | $137.1M | $193.4M | $9.8M | $40.1M | $8.7M | |
| Free Cash Flow | -$82M | -$95.4M | -$144.1M | -$27.9M | -$47.6M | |
URGN
Sector
Market Cap
$994.7M
$28.1M
Price % of 52-Week High
70.83%
51.87%
Dividend Yield
0%
0%
Shareholder Yield
-1.7%
-1.59%
1-Year Price Total Return
92.48%
-17.31%
Beta (5-Year)
1.287
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$22.65
200-day SMA
Buy
Level
$16.56
Bollinger Bands (100)
Buy
Level
17.88 - 23.96
Chaikin Money Flow
Buy
Level
37.4M
20-day SMA
Sell
Level
$22.80
Relative Strength Index (RSI14)
Sell
Level
41.02
ADX Line
Sell
Level
10.77
Williams %R
Buy
Level
-91.746
50-day SMA
Sell
Level
$23.41
MACD (12, 26)
Sell
Level
-0.26
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
63.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.8689)
Sell
CA Score
(Annual)
Level (-5.2211)
Buy
Beneish M-Score
(Annual)
Level (-2.7216)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (5.1921)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Stock Forecast FAQ
In the current month, URGN has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The URGN average analyst price target in the past 3 months is $35.25.
-
Where Will UroGen Pharma Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that UroGen Pharma Ltd. share price will rise to $35.25 per share over the next 12 months.
-
What Do Analysts Say About UroGen Pharma Ltd.?
Analysts are divided on their view about UroGen Pharma Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that UroGen Pharma Ltd. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is UroGen Pharma Ltd.'s Price Target?
The price target for UroGen Pharma Ltd. over the next 1-year time period is forecast to be $35.25 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is URGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for UroGen Pharma Ltd. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of URGN?
You can purchase shares of UroGen Pharma Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase UroGen Pharma Ltd. shares.
-
What Is The UroGen Pharma Ltd. Share Price Today?
UroGen Pharma Ltd. was last trading at $21.27 per share. This represents the most recent stock quote for UroGen Pharma Ltd.. Yesterday, UroGen Pharma Ltd. closed at $21.25 per share.
-
How To Buy UroGen Pharma Ltd. Stock Online?
In order to purchase UroGen Pharma Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get URGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
URGN
Sector
P/E ratio
--
24.20x
PEG ratio
-0.60x
-0.01x
P/B ratio
16.41x
1.84x
Price / LTM sales
10.47x
1.60x
Growth Metrics
URGN
Sector
Revenue growth
9.04%
4.51%
Earnings growth
-26.35%
10.7%
Revenue (5-year growth)
449.77%
6.45%
Earnings forecast
-$0.49
-$0.19
Profitability
URGN
Sector
Profitability FY 2024
$81.5M
$3.5M
Return on invested capital
-209.52%
-32.3%
Return on assets
-66.98%
-28.57%
Return on equity
--
-38.09%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
5
Balance Sheet
URGN
Sector
Total cash
$128.4M
$26M
Short term investments
$64.7M
$25.7M
Total assets
$285.7M
$76.4M
Long term debt
$129.5M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
